Quarterly ResultMay 6, 2026, 11:58 AM
Strata Critical Medical Q1 Net Income $2.15M; Revenue $67.38M
AI Summary
Strata Critical Medical reported a significant turnaround in its first quarter of 2026, achieving a net income of $2.15 million compared to a net loss of $3.49 million in the prior year period. This improvement was driven by an 87.5% increase in total revenue, reaching $67.38 million. The company also saw substantial growth in gross profit and a positive shift in cash flow from operating activities, reflecting the strategic divestment of its Passenger business and the acquisition of Keystone Perfusion Services in 2025.
Key Highlights
- Net income was $2.15 million for Q1 2026, a significant improvement from a $3.49 million net loss in Q1 2025.
- Total revenue increased by 87.5% to $67.38 million in Q1 2026 from $35.95 million in Q1 2025.
- Basic and diluted EPS from continuing operations were $0.03 for Q1 2026, up from $(0.02) in Q1 2025.
- Gross profit doubled to $14.12 million in Q1 2026 from $7.05 million in Q1 2025.
- Net cash provided by operating activities was $3.89 million in Q1 2026, compared to $(0.25) million used in Q1 2025.
- Logistics segment revenue was $47.60 million, and Clinical segment revenue was $19.79 million in Q1 2026.
- Cash and cash equivalents increased to $58.72 million as of March 31, 2026, from $30.97 million at Dec 31, 2025.
- Total liabilities decreased to $41.89 million as of March 31, 2026, from $46.40 million at Dec 31, 2025.
Price Impact
More from SRTA